Discover how OS Therapies' immunotherapy, OST-HER2, originally developed for canine osteosarcoma, shows promising results in fast-tracking treatments for human osteosarcoma. Learn about comparative ...
With the rising burden of cancer in India, awareness around common cancers such as breast, lung and oral cancer has increased ...
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 ...
Please provide your email address to receive an email when new articles are posted on . Inherited mutations in SMARCAL1 are significantly linked to osteosarcoma risk, an analysis of DNA damage repair ...
New research at the University of Guelph offers renewed hope for both human and animal patients fighting osteosarcoma. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback